Rein Therapeutics, Inc.(RNTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
RNTX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Rein Therapeutics, Inc. (RNTX), a Healthcare sector company. RNTX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of RNTX by reported 13-F value include Voss Capital, Cable Car Capital, ADAR1 Capital Management, based on the most recent SEC filings. RNTX trades on the Nasdaq exchange and files with the SEC under CIK 1420565. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RNTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Rein Therapeutics, Inc. directly from SEC EDGAR.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-6.4M
ROIC
Q2 2026
-44.0%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+20.7% YoYOperating Income
+22.2% YoYEPS (Diluted)
+44.2% YoYTotal Assets
-61.2% YoYOp. Cash Flow
+13.1% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $-49.9M +20.7% | $-62.9M -299.7% | $-15.7M +42.4% | $-27.3M -4.5% | $-26.2M +4.3% | $-27.3M |
| Operating Income | $-50.6M +22.2% | $-65.1M -300.0% | $-16.3M +41.1% | $-27.6M -3.9% | $-26.6M -29.8% | $-20.5M |
| EPS (Diluted) | $-0.65 +44.2% | $-1.17 -2.6% | $-1.14 +43.2% | $-2.01 +65.9% | $-5.89 | — |
| Total Assets | $24.2M -61.2% | $62.2M -41.3% | $106.0M +381.7% | $22.0M -54.6% | $48.5M +196.7% | $16.3M |
| Operating Cash Flow | $-19.4M +13.1% | $-22.3M -12.5% | $-19.8M +20.3% | $-24.9M -4.7% | $-23.8M -16.0% | $-20.5M |
| Free Cash Flow | — | — | — | — | $-23.9M -16.7% | $-20.5M |
Get alerted when RNTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Rein Therapeutics, Inc. including:
Top Institutional Holders of RNTX
Voss Capital, LP
$5.5M5,261,921 shCable Car Capital, LP
$5.4M5,195,000 shADAR1 Capital Management, LLC
$4.7M4,500,000 shVANGUARD CAPITAL MANAGEMENT LLC
$3.5M3,377,910 shBIOS Capital Management, LP
$3.1M2,982,375 shIkarian Capital, LLC
$3.1M2,950,000 shGREAT POINT PARTNERS LLC
$2.7M2,575,000 shCITADEL ADVISORS LLC
$2.5M2,438,711 shVelan Capital Investment Management LP
$1.8M1,700,000 shSenvest Management, LLC
$1.3M1,230,895 sh
| Fund | Value | Shares |
|---|---|---|
| Voss Capital, LP | $5.5M | 5,261,921 |
| Cable Car Capital, LP | $5.4M | 5,195,000 |
| ADAR1 Capital Management, LLC | $4.7M | 4,500,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.5M | 3,377,910 |
| BIOS Capital Management, LP | $3.1M | 2,982,375 |
| Ikarian Capital, LLC | $3.1M | 2,950,000 |
| GREAT POINT PARTNERS LLC | $2.7M | 2,575,000 |
| CITADEL ADVISORS LLC | $2.5M | 2,438,711 |
| Velan Capital Investment Management LP | $1.8M | 1,700,000 |
| Senvest Management, LLC | $1.3M | 1,230,895 |
More Healthcare Companies
View all Healthcare →Put RNTX on your watchlist
Track score changes the day Rein Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is RNTX a good stock to buy?
13F Pro's AI-powered analysis of Rein Therapeutics, Inc. (RNTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RNTX are available on the RNTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. RNTX is classified as a small company.
Which hedge funds own RNTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RNTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Rein Therapeutics, Inc.'s investment landscape.